Wednesday May 30th 2018

Arrival and registration	From 08.00
Welcome and opening remarks Chairs: Tore B. Stage, University of Southern Denmark and Kim Brøsen, University of Southern Denmark	09.30
Plenary 1 -Novel methods for assessing drug toxicity Chair: Tore B. Stage, University of Southern Denmark	09.45
iPSC-derived sensory neurons to assess chemotherapy-induced sensory neuropathies Deanna L. Kroetz, UCSF	
From abstract: Doxorubicin uptake in cardiomyocytes is dependent on organic cation transporter 3 Kevin Huang, Ohio State University	
Novel in vitro systems for better prediction of drug metabolism and hepatotoxicity Magnus Ingelman-Sundberg, Karolinska Institutet	
Coffee	11.15
Keynote 1 - Pharmacogenetics of glucose-lowering drugs Chair: Kim Brosen, University of Southern Denmark	11.45
Pharmacogenetics of glucose-lowering drugs Ewan Pearson, Dundee University	
Lunch	12.45
Keynote 2 - Personalized medicine in oncology – success stories from the real World Chair: Tore B. Stage, University of Southern Denmark	13.45
Phenotyping and genotyping in childhood leukemia - precision medicine in an international setting Kjeld Schmiegelow, Copenhagen University Hospital	

Parallel 1 - Next generation sequencing and rare variants in personalized	Parallel 2 - New aspects of P450 variability	14.45
medicine	Chair: Janne T. Backman, University of Helsinki	
Chair: Magnus Ingelman-Sundberg, Karolinska Institutet		
Integrating rare genetic variability into preemptive pharmacogenomic advice Volker Lauschke, Karolinska Institutet	CYP2D6 pharmacogenetics: from a scientific cornucopia towards routine clinical practice Andrea Gaedigk, Children's Mercy Kansas City	
From abstract: Effect of rare single-nucleotide variants on the breast cancer resistance protein Heidi Kidron, University of Helsinki	Cytochrome P450 phenotyping and the microdosing approach Gerd Mikus, Heidelberg University Hospital	
	Clinical significance of cytochrome P450 mediated drug interactions	
Twin studies and systems pharmacology as innovative tools for clinical pharmacokinetics	Kim Brøsen, University of Southern Denmark	
Matthias Schwab, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart and University of Tuehingen, Germany	From abstract: The protein kinase inhibitors midostaurin and nintedanib are time-dependent inhibitors of CYP3A4	
	Anne Filppula, University of Helsinki and Helsinki University Hospital	
Drinks and poster viewing (presenters at posters)		16.45
Beer tasting (additional registration required)		20.00

Thursday May 31st 2018

Plenary 3 - Pharmacoepigenetics and biomarkers Chairs: Ingolf Cascorbi, University of Kiel and Magnus Ingelman-Sundberg, Karolinska Institutet	09.00
miRNAs as mediators of drug resistance Ingolf Cascorbi, University of Kiel	
From abstract: Microrna-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large b-cell lymphoma Hanne Due, Aalborg University Hospital	
DNA Methylation of ADME Genes: Clinical implications Pascale Fisel, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology Stuttgart and University of Tuebingen, Germany	
Diagnostic and prognostic epigenetic biomarkers in cancer. Carmen Jerónimo, University of Porto	
Coffee	11.00
Plenary 4 - Role of the gut in ADME Chairs: Mette Marie Hongaard Christensen, Odense University Hospital and Troels Bergmann, Odense University Hospital	11.30
Gut microbiome interactions with drug metabolism, efficacy, and toxicity Ian Wilson, Imperial College London	
Gut wall metabolism Oliver Hatley, Certara	
Lunch	12.30

	ary 5 - Personalized medicine: Cardiovascular disease ": Niels Jessen, Aarhus Univesity	13.30
	ein biomarkers for cardiovascular conditions - perspectives for personalized medicine? M. Rasmussen, Odense University Hospital	
	n abstract: Selecting pharmacogenetic test for clopidogrel patients Forsström, Abomic Oy	
Inhe	rited cardiac diseases and personalized medicine	
Henn	ing Bundgaard, Copenhagen University Hospital	
	n abstract: GLP-1 receptor variants markedly differentiate glycaemic response to GLP-1 receptor agonists: a direct study of Yesuf Dawed, University of Dundee	
-	note 3 - The role of drug transporters in chemotherapy-induced toxicity r: Tore B. Stage, University of Southern Denmark	15.00
	role of drug transporters in chemotherapy-induced toxicity Sparreboom, Ohio University	
	Poster viewing (presenters at posters)	16.00
	Conference dinner - Hotel Storebælt (additional registration required)	18.30

Friday June 1st 2018

Plenary 6 - Drug transporters Chair: Mikko Niemi, University of Helsinki		09.00
Assessing OCT-function in vivo using 11C-labeled metformin Niels Jessen, Aarhus University		
Pharmacogenomics of transporters; OATP1B1, BCRP, rare variants Mikko Niemi, University of Helsinki		
Со	ffee	10.15
Parallel 3 - Using big data to develop personalized medicine Chairs: Kim Brosen, University of Southern Denmark and Henrik Berg Rasmussen, University of Copenhagen	Parallel 4 - Pharmacogenetics and adverse drug reactions Chair: Per Damkier, Odense University Hospital	10.30
	Challenges to the clinical utility of PGx in the prevention of adverse drug	
Personalized Medicine and big data in Immune Deficiency Jens Lundgren, University of Copenhagen	reactions Henk-Jan Guchelaar, Leiden University Medical Center	
Analyzing drug response data from medical records	Advances in PGx of adverse drug reactions	
Søren Brunak, University of Copenhagen	Munir Pirmohamed, University of Liverpool	
From abstract: Clinical implementation of personalized medicine by novel approaches in therapeutic drug monitoring (TDM) Erik Eliasson, Karolinska Institutet	From abstract: Genome-wide association study of pandemrix-induced narcolepsy in sweden - a possible role for glial derived neurotrophic factor (GDNF) Mia Wadelius, Uppsala University	
Danish National Health Registries and Pharmacogenetics in Psychiatry		
Christiane Gasse, Aarhus University	The genetic basis of drug-induced liver injury Ann Daly, University of Newcastle	
Closing remarks and awards		12.15

Lunch – grab and go